(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
9 September 2005 (09.09.2005)

PCT

(10) International Publication Number
WO 2005/082350 A1

(51) International Patent Classification[7]: A61K 31/341, 31/40, 31/38, A61P 29/00, 11/06

(21) International Application Number: PCT/US2005/004108

(22) International Filing Date: 10 February 2005 (10.02.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/546,011 20 February 2004 (20.02.2004) US

(71) Applicants *(for all designated States except US)*: **AVENTIS PHARMACEUTICALS INC.** [US/US]; 300 Somerset Corporate Boulevard, Bridgewater, NJ 08807-2854 (US). **AVENTIS PHARMA DEUTSCHLAND GMBH** [DE/DE]; Bruningstrasse 50, 65926 Frankfurt (DE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **MINNICH, Anne** [US/US]; 2 Knoll Court, Flemington, NJ 08822 (US). **KUNTZWEILER, Theresa** [US/US]; 18 Mullens Lane, Bernardsville, NJ 07924 (US). **EISHINGDRELO, Haifeng** [US/US]; 17 Fletcher Drive, Montville, NJ 07045 (US). **ANGELASTRO, Michael** [US/US]; 212 Porter Way East, Bridgewater, NJ 08807 (US). **LANG, Han-Jochen** [DE/DE]; Ruedesheimer Str. 7, D-65719 Hofheim-Wallau (DE).

(74) Agents: **KRUPEN, Karen, I.** et al.; Aventis Pharmaceuticals Inc., Route 202-206||P. O. Box 6800, Bridgewater, NJ 08807-0800 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations*
— *of inventorship (Rule 4.17(iv)) for US only*

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: FUROSEMIDE DERIVATIVES AS MODULATORS OF HM74 AND THEIR USE FOR THE TREATMENT OF INFLAMMATION



(I)

(57) Abstract: Furosemide-like molecules with agonist activity on the HM74 receptor having the following structure formula (I); and their use to treat inflammatory disorders.

WO 2005/082350 A1